EGFR and neoplasm: Univariate analyses of patients with EGFR mutations in cfDNA identified the L858R mutation in tumor tissue or in cfDNA as a marker of shorter OS (hazard ratio, 2.70; P < .001) and PFS (HR, 2.04 [95% CI, 1.20 to 3.48]; P = .008) [74].